1. Romani, Patrizia, Nirchio, Nunzia, Arboit, Mattia, Martello, Graziano, Dupont, Sirio. 2022. Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance. In Nature cell biology, 24, 168-180. doi:10.1038/s41556-022-00843-w. https://pubmed.ncbi.nlm.nih.gov/35165418/
2. Zhao, Shuhua, Cheng, Lu, Shi, Yuan, Yun, Qinghui, Yang, Hong. 2021. MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. In Cell death & disease, 12, 18. doi:10.1038/s41419-020-03336-6. https://pubmed.ncbi.nlm.nih.gov/33414447/
3. Zhao, Shuhua, Zhang, Xiaohong, Shi, Yuan, Li, Jia, Yang, Hong. 2020. MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer. In Journal of experimental & clinical cancer research : CR, 39, 286. doi:10.1186/s13046-020-01802-9. https://pubmed.ncbi.nlm.nih.gov/33317572/
4. Zhou, Luyu, Li, Ruibei, Liu, Cuiyun, Zhao, Yanfang, Wang, Kun. 2017. Foxo3a inhibits mitochondrial fission and protects against doxorubicin-induced cardiotoxicity by suppressing MIEF2. In Free radical biology & medicine, 104, 360-370. doi:10.1016/j.freeradbiomed.2017.01.037. https://pubmed.ncbi.nlm.nih.gov/28137654/
5. Xie, Chaozheng, Li, Kang, Li, Ya, Wang, Wang, Wei, Zhengqiang. 2022. CRISPR-based knockout screening identifies the loss of MIEF2 to enhance oxaliplatin resistance in colorectal cancer through inhibiting the mitochondrial apoptosis pathway. In Frontiers in oncology, 12, 881487. doi:10.3389/fonc.2022.881487. https://pubmed.ncbi.nlm.nih.gov/36106106/
智鼠故事 
